Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
XPC
REST API REST API
Homo sapiens
XPC is differentially expressed in 242 experiments: 95 organism parts: bone marrow, brain, ... (93 more);, 142 disease states: normal, lung adenocarcinoma, ... (140 more);, 63 cell types 249 cell lines 39 compound treatments and 71 other conditions.
Synonyms XPCC, RAD4
Orthologs Xpc (Rattus norvegicus)   Xpc (Mus musculus)   XPC (Bos taurus)   xpc (Danio rerio)   RAD4 (Saccharomyces cerevisiae)   ENSCING00000013290 (Ciona intestinalis)   XPC (Gallus gallus)   XPC (Xenopus laevis)   XPC (Canis familiaris)   (Compare orthologs)
Gene Ontology Term intra-S DNA damage checkpoint, nucleotide-excision repair, DNA repair, cytoplasm, damaged DNA binding, single-stranded DNA binding, nucleus, response to drug, nucleoplasm, cell cycle checkpoint, response to DNA damage stimulus, response to UV-B, bubble DNA binding, loop DNA binding, nucleotide-excision repair, DNA damage recognition, nucleotide-excision repair, DNA damage removal, XPC complex
InterPro Term DNA_repair_Rad4_DNA-bd_3, DNA_repair_Rad4_DNA-bd_2, DNA_repair_Rad4_DNA-bd_1, DNA_repair_Rad4_subgr, Rad4/PNGase_transGLS-fold
UniProt Accession D2CPJ1, D2CPJ0, D2CPJ8, D2CPJ3, D2CPI8, D2CPI9, D2CPK4, D2CPK2, D2CPK1, Q01831, F5GWY3, E7EUB5, E9PB96, E9PH69
Gene-Disease Assocation XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C; XPC
Search EB-eye ENSG00000154767
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-22541, E-MEXP-1251, E-MTAB-25, E-GEOD-1563, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (36 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
MDA468
2
E-MEXP-440, E-MTAB-62
MDA-MB-231
1
2
E-TABM-420, E-MTAB-62, E-GEOD-5823
YPAC
1
E-MTAB-37
Hep-2
1
E-MTAB-62
ew24 cell line, lentivirus treated
1
E-MTAB-62
243 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-20677, ... (31 experiments)

Factor Value U/D Experiments
adult native RPE from 89 y.o. donor
1
E-GEOD-18811
platelet
1
E-GEOD-2006
keratinocyte
1
E-GEOD-3204
PBMCs
1
E-GEOD-20677
primary fibroblast
1
E-MEXP-66
parental foreskin cells
1
E-GEOD-20033
57 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-25, E-GEOD-22529, E-GEOD-15960, E-MEXP-2069, ... (42 experiments)

Factor Value U/D Experiments
prostate cancer
2
E-MTAB-62, E-GEOD-6919
rhabdomyosarcoma
2
E-MTAB-62, E-MTAB-37
control
2
E-GEOD-21912, E-GEOD-16728
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
136 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (24 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-5824, E-GEOD-2803, E-TABM-868, E-GEOD-1740, E-GEOD-412, ... (7 experiments)
control
2
E-GEOD-4006, E-GEOD-5339
lipopolysaccharide
2
E-TABM-868, E-GEOD-3720
saline
1
E-GEOD-3026
unknown
1
E-GEOD-7307
dimethyl sulfoxide
1
E-GEOD-5824
33 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
28 years
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-16363, E-GEOD-21610, E-GEOD-512 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-22541, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-GEOD-361, ... (6 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-21750, E-TABM-868, E-TABM-601, E-GEOD-1153, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-6432, E-GEOD-5681, E-MEXP-2657, E-GEOD-12773, ... (11 experiments)

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-360

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1460

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-GEOD-22541, E-GEOD-1561, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.314 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM